[Antiastenic effect of sequential levocarnitine and acetylcarnitine therapy in patients with cardiovascular diseases].

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)

The results obtained indicate that in such comorbid patients, the use of LC and ALC reduces the severity of AS manifestations, and the established endotheliotropic properties of the drugs allow them to be recommended as part of the complex personalized therapy of patients with cardiovascular diseases.

Keyphrases

cardiovascular disease
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
simultaneous determination
patient reported outcomes
mesenchymal stem cells